On May 23, 2022, a news release from Pfizer and BioNTech reported that preliminary findings from a clinical trial of children younger than five years-old showed that three doses of the companies’ COVID-19 vaccine produced a strong enough immune response — 80 percent effective in preventing symptomatic infection in a subset of the 1,678 trial participants, who were six months through four years old — to meet the criteria for regulatory authorization.

To read more from the New York Times, click here.